Trial
NCT03504917
A Study of Balovaptan in Adults With Autism Spectrum Disorder With a 2-Year Open-Label Extension
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Hoffmann-La Roche
Collaborators
—
Condition
Autism Spectrum Disorder
Intervention
Balovaptan
Why stopped
A futility analysis assessed that the study is highly unlikely to meet the pre-defined primary objective of the study. No new safety concerns were identified.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-10-27